What does VIESVILLE PHARMA do?

VIESVILLE PHARMA is a logistics company in Pont-à-Celles. Private Limited, started on 7 May 1991, 1 establishment.

What is the address of VIESVILLE PHARMA?

The registered office of VIESVILLE PHARMA is located at Rue Albert 1er(VIE) 11A, 6230 Pont-à-Celles.

Is VIESVILLE PHARMA still active?

Yes. According to the CBE (31 October 2026) VIESVILLE PHARMA is active, legal situation “Normale toestand”, started on 7 May 1991.

Is VIESVILLE PHARMA registered on Peppol?

Yes, VIESVILLE PHARMA is registered on the Peppol network with ID 0208:0444043927.

What is the enterprise number of VIESVILLE PHARMA?

The enterprise number of VIESVILLE PHARMA is BE0444043927.

When was VIESVILLE PHARMA founded?

VIESVILLE PHARMA was founded on 7 May 1991.

Who are the directors of VIESVILLE PHARMA?

According to the 2025 annual accounts, the directors of VIESVILLE PHARMA are: Pascale WATELET.

Is VIESVILLE PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 May 1991; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did VIESVILLE PHARMA make in 2025?

VIESVILLE PHARMA posted a profit after taxes of € 51,339 in financial year 2025.

What is the revenue of VIESVILLE PHARMA?

As a small company, VIESVILLE PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 136,618.

How much does an employee at VIESVILLE PHARMA earn?

The average wage cost per full-time employee at VIESVILLE PHARMA was € 45,300 in 2025: staff costs of € 54,308 for 1.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does VIESVILLE PHARMA have?

According to the 2025 annual accounts, VIESVILLE PHARMA has 1.2 full-time equivalents (FTE).

VIESVILLE PHARMA (Private Limited) - Pont-à-Celles

Dossier VIESVILLE PHARMA, printed on 31 October 2026 from databakkes.be/en/0444043927/viesville-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 1.7 to 1.2.

Financials

Financial year 2025

VIESVILLE PHARMA from Pont-à-Celles, company number BE0444043927, closed financial year 2025 with a result of € 51,339 after tax. For that financial year VIESVILLE PHARMA recorded a gross margin of € 136,618 and equity of € 393,723. Compared with financial year 2024, the result moved from € 54,054 to € 51,339. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.

What it is worth Growing

€ 393,723

▲ 15% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 51,339

▼ 5% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 193,375

▼ 2% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 387,518.

People and assets in 2025

Full-time equivalents

1.2

▼ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 54,308

▼ 11% vs 2024

€ 45,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 10,933

▲ € 10,188 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 25,956

▼ 66% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 20,044

▼ 1% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 138,819 Gross margin 2022: € 138,819 First fiscal year in the series	€ 130,935 Gross margin 2023: € 130,935 ▼ 6% vs 2022 (€ 138,819) Unfavourable step	€ 148,151 Gross margin 2024: € 148,151 ▲ 13% vs 2023 (€ 130,935) Favourable step	€ 136,618 Gross margin 2025: € 136,618 ▼ 8% vs 2024 (€ 148,151) Unfavourable step	▼ 8%
Profit after taxes	€ 44,700 Profit after taxes 2022: € 44,700 First fiscal year in the series	€ 27,510 Profit after taxes 2023: € 27,510 ▼ 38% vs 2022 (€ 44,700) Unfavourable step	€ 54,054 Profit after taxes 2024: € 54,054 ▲ 96% vs 2023 (€ 27,510) Favourable step	€ 51,339 Profit after taxes 2025: € 51,339 ▼ 5% vs 2024 (€ 54,054) Unfavourable step	▼ 5%
Equity	€ 260,819 Equity 2022: € 260,819 First fiscal year in the series	€ 288,330 Equity 2023: € 288,330 ▲ 11% vs 2022 (€ 260,819) Favourable step	€ 342,384 Equity 2024: € 342,384 ▲ 19% vs 2023 (€ 288,330) Favourable step	€ 393,723 Equity 2025: € 393,723 ▲ 15% vs 2024 (€ 342,384) Favourable step	▲ 15%
Total debts	€ 185,627 Total debts 2022: € 185,627 First fiscal year in the series	€ 175,965 Total debts 2023: € 175,965 ▼ 5% vs 2022 (€ 185,627) Favourable step	€ 117,310 Total debts 2024: € 117,310 ▼ 33% vs 2023 (€ 175,965) Favourable step	€ 75,883 Total debts 2025: € 75,883 ▼ 35% vs 2024 (€ 117,310) Favourable step	▼ 35%
Cash	€ 176,811 Cash 2022: € 176,811 First fiscal year in the series	€ 180,557 Cash 2023: € 180,557 ▲ 2% vs 2022 (€ 176,811) Favourable step	€ 197,944 Cash 2024: € 197,944 ▲ 10% vs 2023 (€ 180,557) Favourable step	€ 193,375 Cash 2025: € 193,375 ▼ 2% vs 2024 (€ 197,944) Unfavourable step	▼ 2%
Land & buildings	€ 92,839 Land & buildings 2022: € 92,839 First fiscal year in the series	€ 89,651 Land & buildings 2023: € 89,651 ▼ 3% vs 2022 (€ 92,839) Unchanged	€ 77,675 Land & buildings 2024: € 77,675 ▼ 13% vs 2023 (€ 89,651) Unchanged	€ 69,446 Land & buildings 2025: € 69,446 ▼ 11% vs 2024 (€ 77,675) Unchanged	▼ 11%
Retained profit	€ 254,614 Retained profit 2022: € 254,614 First fiscal year in the series	€ 282,124 Retained profit 2023: € 282,124 ▲ 11% vs 2022 (€ 254,614) Favourable step	€ 336,179 Retained profit 2024: € 336,179 ▲ 19% vs 2023 (€ 282,124) Favourable step	€ 387,518 Retained profit 2025: € 387,518 ▲ 15% vs 2024 (€ 336,179) Favourable step	▲ 15%
Bank debt	€ 42,970 Bank debt 2022: € 42,970 First fiscal year in the series	€ 24,554 Bank debt 2023: € 24,554 ▼ 43% vs 2022 (€ 42,970) Favourable step	€ 6,138 Bank debt 2024: € 6,138 ▼ 75% vs 2023 (€ 24,554) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 6,138) Favourable step	▼ 100%
Balance sheet total	€ 447,093 Balance sheet total 2022: € 447,093 First fiscal year in the series	€ 464,941 Balance sheet total 2023: € 464,941 ▲ 4% vs 2022 (€ 447,093) Unchanged	€ 460,341 Balance sheet total 2024: € 460,341 ▼ 1% vs 2023 (€ 464,941) Unchanged	€ 470,253 Balance sheet total 2025: € 470,253 ▲ 2% vs 2024 (€ 460,341) Unchanged	▲ 2%
Employees (FTE)	1.6 Employees (FTE) 2022: 1.6 First fiscal year in the series	1.7 Employees (FTE) 2023: 1.7 ▲ 0.1 vs 2022 (1.6) Unchanged	1.5 Employees (FTE) 2024: 1.5 ▼ 0.2 vs 2023 (1.7) Unchanged	1.2 Employees (FTE) 2025: 1.2 ▼ 0.3 vs 2024 (1.5) Unchanged	▼ 0.3

Key figures of VIESVILLE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VIESVILLE PHARMA?

What happened at VIESVILLE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 26, 2026 New annual accounts for financial year 2025: profit of € 51,339 (▼ 5% vs 2024). filed late Source: NBB ↗
May 23, 1991 New establishment in Pont-à-Celles. KBO
May 7, 1991 Start of the company according to the CBE. KBO

In short

From € 44,700 profit in 2022 to € 51,339 profit in 2025.

Paid € 49,651 in corporate taxes since 2022.

Best year ever: 2024, with € 54,054 profit.

On average € 113,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Pascale WATELET

VIESVILLE PHARMA

Behind VIESVILLE PHARMA is Pascale WATELET.

Directors

According to the 2025 annual accounts

Pascale WATELET

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Albert 1er(VIE) 11A

6230 Pont-à-Celles

2.052.791.697

Rue Albert 1er(VIE) 11 A

6230 Pont-à-Celles

Active since 23 May 1991

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0444.043.927

VAT number

BE 0444.043.927

Registered office

Rue Albert 1er(VIE) 11A, 6230 Pont-à-Celles

Names & denominations

VIESVILLE PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

7 May 1991

Peppol

Active · Active since 22 Dec 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

VIESVILLE PHARMA

Warning lights

Financials

What happened to VIESVILLE PHARMA?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions